A rebuttal to “The proximal origin of SARS-CoV-2”: Covid-19 is plausibly from a manmade virus. Emergency regulatory reform for stopping epidemics

Timothy R Stout
DOI: https://doi.org/10.31219/osf.io/usx58
2020-06-03
Abstract:A recent letter in Nature Medicine (www.doi.org/10.1038/s41591-020-0820-9) claims that genomic analysis of SARS-CoV-2 shows that it is clearly not manmade and that natural evolutionary causes are adequate to explain its appearance. By contrast the case is made here that genomic analysis of the virus shows that directed evolution, a human engineering process honored by the 2018 Nobel Prize in Chemistry, provides superior explanation for its origin. The simultaneous appearances of a new RBD backbone, a new polybasic cleavage sight, new fusion improvements, asymptomatic transmission, and an initial stable mutation rate indicative of mature adaptation to a host work together to lead to a common conclusion: directed evolution provides more plausible explanation of the virus’s origin than does natural evolution. The major concern here is not who might have made the virus, but rather that technology already exists and is already well-understood throughout the world which is capable of creating new, future pandemics and appear to be the proximal cause of Covid-19. A pandemic emerges because there are no effective drugs to stop it. Traditional new-drug approval laws effectively prevent newly developed drugs designed to fight a pandemic from being used soon enough to prevent it from becoming entrenched. The Stout Protocol presented here provides a plausible solution to this problem: A Procedural Specification defines the drug approval protocol and is converted into a software program which is then downloaded into a computer. No personal interactions are needed between the government approval agency and the sponsor of a new drug; the computer controls interactions. An approved drug sponsor is immediately given a limited number of volunteers for direct human testing. A physician monitors the results and reports them on a scorecard. The computer processes the scorecards and immediately computes a revised score based on the physicians’ reports. The score determines how many patients a company is allowed to treat and how much monitoring for effectiveness and adverse effects is required after a drug is administered. If a score drops below a predefined value, the drug is removed from the program.
What problem does this paper attempt to address?